Rna Diagnostics Inc. is a molecular diagnostics company developing diagnostic tools to assist in the management of cancer chemotherapy.

The company’s first product, RNA Disruption Assay™ (RDA™), is a novel test that helps oncologists to rapidly assess the effectiveness of cancer chemotherapy. RDA™ can determine whether chemotherapy is working effectively in the individual patient early in treatment thereby guiding clinical decision making.

Highlights include:

• The only diagnostic tool that predicts early in treatment how a patient will respond in chemotherapy
• Potential to radically improve cancer chemotherapy management
• RDA™ spares non-responders from harmful adverse effect of chemotherapy while improving clinical outcomes
• RDA™ provides significant cost savings for healthcare payers
• Proof of principle established in a major multi-centre breast cancer clinical trial
• Significant advantages over competing chemotherapy management technologies